High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.

CONCLUSIONS: FAK and Aurora kinase B inhibitors synergistically impair Ewing sarcoma cell viability and significantly inhibit tumor progression. This study provides preclinical support for the consideration of a clinical trial testing the safety and efficacy of this combination for patients with Ewing sarcoma.
PMID: 30979745 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 11, 2019 Category: Cancer & Oncology Authors: Wang S, Hwang EE, Guha R, O'Neill AF, Melong N, Veinotte CJ, Saur Conway A, Wuerthele K, Shen M, McKnight C, Alexe G, Lemieux ME, Wang A, Hughes E, Xu X, Boxer MB, Hall MD, Kung AL, Berman JN, Davis MI, Stegmaier K, Crompton BD Tags: Clin Cancer Res Source Type: research